Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for Ga-68 DOTATATE-positive non-functioning pituitary macroadenoma
NL-OMON27861Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised trial in non-functioning pituitary macroadenoma (NFPM) comparing Lanreotide with Placebo (2 arms). Primary endpoint: Change in cranio-caudal NFMA size. Started Nov 2015; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
non-functioning pituitary macroadenoma (NFPM)
Beyond the preview
Go deeper on NL-OMON27861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27861.